- Home
- VERV
as 06-20-2025 4:00pm EST
Verve Therapeutics Inc clinical-stage company developing a new class of genetic medicines for cardiovascular disease, or CVD, with the potential to transform treatment from chronic therapies to single-course gene editing medicines. The current paradigm of chronic care is fragile requiring rigorous patient adherence, extensive healthcare infrastructure, and regular healthcare access, and leaves many patients without adequate care. Its pipelines are PCSK9, ANGPTL3, and LPA. The group has one reportable segment relating to the research and development of gene-editing medicines. The segment derives its current revenues from research and development collaborations.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 384.2M | IPO Year: | 2021 |
| Target Price: | $14.75 | AVG Volume (30 days): | 7.8M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.10 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.87 - $11.40 | Next Earning Date: | 08-07-2025 |
| Revenue: | $59,613,000 | Revenue Growth: | 271.44% |
| Revenue Growth (this year): | 27.75% | Revenue Growth (next year): | -68.11% |
Stock Insider Trading Activity of Verve Therapeutics Inc. (VERV)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Nickerson Joan | VERV | Chief Administrative Officer | Apr 1 '25 | Sell | $4.15 | 2,777 | $11,524.55 | 17,420 | |
| Dorval Allison | VERV | Chief Financial Officer | Apr 1 '25 | Sell | $4.15 | 3,350 | $13,902.50 | 13,280 | |
| Ashe Andrew D. | VERV | See Remarks | Apr 1 '25 | Sell | $4.15 | 2,681 | $11,126.15 | 348,828 | |
| Kathiresan Sekar | VERV | Chief Executive Officer | Apr 1 '25 | Sell | $4.15 | 9,822 | $40,761.30 | 346,686 | |
| Lister Troy | VERV | Chief Scientific Officer | Apr 1 '25 | Sell | $4.15 | 2,189 | $9,084.35 | 6,952 | |
| Politi Jason | VERV | Chief Technical Ops. Off. | Apr 1 '25 | Sell | $4.15 | 3,235 | $13,425.25 | 14,226 |
Latest Verve Therapeutics Inc. News
VERV Breaking Stock News: Dive into VERV Ticker-Specific Updates for Smart Investing
Motley Fool
a day ago
Why Lilly's Bid for Verve Therapeutics Sent the Stock Soaring This Week
Zacks
2 days ago
What is the Intent Behind Eli Lilly's Recent M&A Deals Spree?
TipRanks
2 days ago
SanDisk initiated, Analog Devices upgraded: Wall Street’s top analyst calls
TipRanks
3 days ago
Verve Therapeutics downgraded to Hold from Buy at Canaccord
Zacks
3 days ago
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
MT Newswires
3 days ago
Canaccord Genuity Downgrades Verve Therapeutics to Hold From Buy
MT Newswires
3 days ago
William Blair Downgrades Verve Therapeutics to Market Perform From Outperform
MT Newswires
3 days ago
Jefferies Downgrades Verve Therapeutics to Hold From Buy, Adjusts Price Target to $11 From $28
Compare VERV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VERV Verve Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.